



# Investor Presentation

---

21 November 2018

# MMJ Group Holdings Limited

Global cannabis investment company

Corporate Details	Portfolio	Investment Approach
<p>ASX: MMJ</p> <p>Listed investment company (“LIC”); to be reinstated to official quotation by the ASX tomorrow</p> <p>Sydney HQ – team of 3</p> <p>23¢ post-tax NTA per share (down from 31¢ reported on 22 October 2018; mostly due to lower Harvest One share price)</p> <p>\$56m AUM (includes \$1.6m corporate cash at bank)</p>	<p>10 minority investments (2 public; 8 private)</p> <p> 7 Legal recreational market</p> <p> 1 Hemp-derived CBD</p> <p> 2 Emerging medical market</p>	<p>Invest across the value chain</p> <p>Minority stakes</p> <p>Seed &amp; venture capital</p> <p>Growth &amp; pre-IPO funding</p> <p>Divestments provide liquidity</p>

Note: “NTA” is unaudited net tangible assets after tax (on both realised and unrealised gains/losses). “AUM” is unaudited market value of assets under management. AUM is based on the most recent closing share prices for public companies and the most recent funding round share prices for private companies converted into Australian dollars at the relevant prevailing foreign exchange rates. AUM also includes the unrealised gain arising from the positive difference between the most recent share price and the exercise price of unexercised warrants (where applicable). All figures in this presentation are as at **20 November 2018** unless stated otherwise.



# Portfolio currently focused on North America

Recreational cannabis sales were legalised in Canada in October 2018

Country of Origin										
Investee	 <b>HARVEST ONE</b> TSXV:HVT	 MediPharm Labs TSXV:LABS	 WEEDME	 Emoark	 FIRE & FLOWER	 BEVCANNA	 Bien	 VITAGENNE™	 cannabis access CLINICS	 MM MARTHA JANE — MEDICAL —
Business	Brands	Extraction	Cultivation	Extraction	Retail Stores	Beverages	R&D	Hemp-derived CBD	Clinics	Extraction
% of AUM	50%	17%	11%	5%	5%	2%	1%	2%	2%	1%

# North American target markets are attractive

Large markets for recreational cannabis and hemp-derived CBD products



Source: *Hemp Business Journal* estimates (\$ mil., consumer sales)

Source: Deloitte 2018 cannabis report "A society in transition, an industry ready to bloom". Projected legal market size is based on forecast sales for the whole market in 2019.

**Important Note:** These are not forecasts for MMJ nor its investees. MMJ's investees participate in these markets and are aiming to capture some market share.


# Portfolio company leadership is impressive

Experienced and highly motivated senior executives with strong track records

									
									
Grant Froese	Pat McCutcheon	Ed Jamieson	Bruce Dawson-Scully	Trevor Fencott	Marcello Leone	Curtis Leifso	Ram Venkat	Dr Sanjay Nijhawan	Nelson Reynolds
38-year career at Loblaw Companies Limited, Canada's food and pharmacy leader	15-years in the pharmaceutical industry in top sales roles, successfully launching a wide range of medical products	Recent CEO of Medical Pharmacies Group Limited in Canada	Founder and ex-CEO of WeedMD (TSXV:WMD)	Co-founded Mettrum Health, Canada's 2nd largest licensed cannabis producer before its sale to Canopy Growth for \$430m in 2017	CEO and President of RYU Apparel (TSXV:RYU) and owner of Naturo Group Investments	Ph.D. from the University of Calgary, Canada and experienced in working in demanding start-up environments	Co-founded a US-based cannabis and hemp-infused beverages company and a super-premium vodka company	Previous Head of Clinical Development at Primary Healthcare Limited and responsible for their extensive network of clinics around Australia	Extensive experience with ASX listed companies; holds a degree with majors in Pharmacology and Microbiology

# Investments sit across most of the value chain


Capital is allocated to potential market leaders, consolidators and takeover targets



# Capital allocation is actively managed

Currently skewed to cannabis brands and extraction facilities

## Capital Allocation



## Warrants

Warrants held by MMJ <i>Unaudited figures</i>	Exercise cost of warrants (CAD\$m)	Current Unrealised Gain (CAD\$m)	Warrants expiry
MediPharm Labs (TSXV:LABS)	\$ 3.5	1.1	Oct 2020
Weed Me	\$ 3.0	1.5	Dec 2020
Embark Health	\$ 1.8	n/a	Nov 2020
Fire & Flower	\$ 1.3	0.6	Apr 2020
Bien	\$ 1.0	n/a	May 2021
<b>Total</b>	<b>\$ 10.6</b>	<b>3.2</b>	

Warrants provide potential future upside and the option for MMJ to increase the capital allocation of existing investments

*Note: Capital allocation pie chart is based on AUM. No warrants have been exercised to date by MMJ. The realisation of potential gains is subject to there being capital available to MMJ to exercise the warrants.*

# Outlook is positive

Significant developments are expected across the portfolio

Investee	Outlook for the next 12 months
Harvest One (TSXV: HVT)	<ul style="list-style-type: none"> <li>• Cultivation capacity: targeting 20,000 kg per annum of owned cannabis cultivation capacity by the end of the 2019 calendar year</li> <li>• Satipharm: annual revenue run-rate of CAD\$10 million by 30 June 2019</li> <li>• Dream Water: annual revenue run-rate to double to CAD\$12 million in the next 6 to 8 months</li> <li>• Burb: 8 to 10 retail cannabis stores targeted in British Columbia by mid-2019 calendar year</li> <li>• Capital: CAD\$50 million of cash at bank and no debt (as at 28 September 2018)</li> </ul>
MediPharm Labs (TSXV: LABS)	<ul style="list-style-type: none"> <li>• Increase customised processing capacity to an expected 250,000kg of dry cannabis per year by the end of Q2/CY19 (fully-funded)</li> <li>• Continue to sign up new customers</li> </ul>
Weed Me	<ul style="list-style-type: none"> <li>• Build out their cannabis cultivation facility in Ontario</li> <li>• Receive a retail sales licence</li> </ul>
Embark Health	<ul style="list-style-type: none"> <li>• Build their cannabis extraction and product manufacturing facility in British Columbia</li> <li>• Become a Licensed Dealer</li> </ul>
Fire & Flower	<ul style="list-style-type: none"> <li>• List on the TSX-V</li> <li>• Continue to establish retail cannabis stores across Canada</li> </ul>
BevCanna	<ul style="list-style-type: none"> <li>• Build their cannabis beverages manufacturing facility in British Columbia</li> <li>• Become an ACMPR Licensed Producer</li> </ul>
Bien	Create proprietary products at their cannabis derivatives manufacturing facility in Alberta
VitaGenne	Commence sales of their hemp-derived CBD tinctures, gel capsules, pain and repairing creams in the United States
Cannabis Access Clinics	Continue to establish new medical cannabis clinics across Australia
Martha Jane Medical	Build their Tasmanian cannabis extraction business subject to obtaining a manufacturing licence (application in process) and further funding

# Disclaimer

## DISCLAIMER

This presentation has been prepared by MMJ Group Holdings Limited (the “Company” or “MMJ”) (ABN 91 601 236 417). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

## FUTURE MATTERS

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

## US DISCLOSURE

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.